IndiGo Launches Co-Branded Credit Card to Boost Loyalty Program
IndiGo has introduced its first co-branded credit card tied to its year-old loyalty program, BluChip, marking another step in its push to evolve from a budget domestic airline to a global player.
The airline is launching the credit card in partnership with Kotak Mahindra Bank. The card lets customers earn extra loyalty points on both flights and everyday purchases like dining and entertainment.
Before it had the BluChip loyalty program, IndiGo offered 6E Rewards, a program tied to co-branded cards with HDFC and Kotak, which allowed travelers to earn points through spends.
This launch also fits into a wider trend of airlines using loyalty programs and credit card tie-ups to improve customer retention, increase direct bookings, and expand revenue streams beyond ticket sales. But for IndiGo, which until recently focused squarely on low-cost travel, this also marks a shift in strategy.
Why IndiGo Is Doing This Now? Over the last three years, IndiGo has been repositioning itself. Known for offering no-frills travel within India, it has since added international routes, launched a business-style product (IndiGoStretch), and explored partnerships with global airlines and service providers.
IndiGo also launched the loyalty program, BluChip in late 2024 as part of that transition. So far, the airline says over 3.5 million people have signed up. Now, with the addition of credit cards, IndiGo is trying to make the program more valuable.
What Do the Cards Offer? IndiGo is offering two types of credit cards:
IndiGo Kotak Credit Card: Designed for people who want basic travel perks along with everyday use. Spending INR 600,000 ($6,979) per year could earn over 30,000 BluChips. IndiGo Kotak Premium Credit Card: Aimed at frequent flyers and bigger spenders. This card
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Sino Biopharma spends $951m to acquire China-based LaNova Medicines
Hong Kong-listed Sino Biopharmaceutical will acquire China-based oncology specialist LaNova Medicines in a deal that will not exceed $951m, representing one of the largest transactions within the Asia-Pacific pharmaceutical arena this year. Sino already owns a 4.91% stake courtesy of an investment in November 2024, with the company now seeking to purchase the remaining 95.09% it does not own. At the time, Sino spent 142 million yuan ($19.80m) to initiate its ownership involvement with the biotech. The net payment made by Sino to acquire LaNova will be approximately $500.9m, a figure that excludes the estimated cash and bank deposits, according to a company document outlining the terms of the transaction. Following the completion of the nearly billion-dollar deal, LaNova Medicines will become an indirect wholly owned subsidiary of Sino. A timeline of 30 business days has been set by the companies to finalise the deal. Sino revealed the acquisition agreement after trading hours on 15 July. The share price in the company had climbed 3.6% by market close. LaNova's drug development focuses on tumour immunity and the tumour microenvironment. The company has particular emphasis on antibody-drug conjugates (ADCs) and has built several platforms within this modality. Sino stated the acquisition would strengthen its research and development capabilities, subsequently enhancing competitiveness and innovation in the oncology market. LaNova's pipeline has already been raided twice by US big pharma companies. In 2023, AstraZeneca licensed LM-305, a G-protein targeting-ADC, for $600m. A year later, MSD outlaid more than $3bn to secure global rights to LM-299, an anti-PD-1/VEGF bispecific antibody. According to Sino, LaNova Medicines has two projects in the registration clinical stage, six projects in the Phase I/II clinical trial stage, and more than ten projects in the preclinical research stage. In a statement, Sino said: 'Through the in-depth synergy and integration of the advantageous resources of both parties, not only will the potential value of LaNova Medicines be fully released, but also [Sino's] innovation capability will be comprehensively enhanced." The company added that the transaction will help towards its 'strategic goal of advancing towards a world-class innovative pharmaceutical enterprise'. China's economy grew 5.2% year-on-year in Q2, defying the lingering effects of US President Trump's trade war and reinforcing its position as the world's top exporter. This economic resilience is mirrored in China's growing role in the global oncology market. Despite economic pressures, licensing promising drug candidates from Chinese biotechs is becoming a well-trodden path for many US big pharma companies. Licensing deals between US and Chinese biopharma companies hit record highs last year, a 280% increase from 2020, according to analysis by GlobalData. Across big pharma, transactions rose 66% from $16.6bn in 2023 to $41.5bn in 2024, demonstrating that China is still the go-to place to discover pipeline candidates. For deals specific to US companies, the analysis found that total deal value rose from $15.7bn in 2023 to $21.3bn in 2024. GlobalData is the parent company of Pharmaceutical Technology. "Sino Biopharma spends $951m to acquire China-based LaNova Medicines" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Travel Weekly
an hour ago
- Travel Weekly
How Silversea is streamlining its expedition cruise experience
Teri West Galapagos cruising got cushier this month for those sailing with Silversea's Silver Origin. The cruise line is now providing passengers with charter flights in Ecuador from Quito to San Cristobal Island, a two-hour trip that forgoes the previous layover in Guayaquil. It is becoming ever clearer that Silversea believes luxury in expedition requires eliminating, as much as possible, unpredictability and discomfort before and after the cruise. For Antarctica cruises, the line offers charter flights from Chile and will soon also host guests before their flight at a Silversea-built and owned hotel. In the expedition space, the trick in crafting the journey is leaving room for error, so Silversea's pre- and post-cruise services are a true value, said David Lauwers, a luxury cruise and expedition travel advisor at Q Cruise + Travel. "It's padding out an expedition," he said. "It isn't like going to Europe, where you can get on the next flight, there's loads of carriers and it's not a problem." Lauwers said he likes to direct clients toward Silversea because it eliminates so many of the logistical challenges involved in ensuring his customers are aboard the ship when it leaves the homeport. The services also differentiate Silversea from competitors, and once guests try the Silversea flights there is a high satisfaction rate, Lauwers said. They find the plane ride to be an exciting kickoff for the cruise itself, with Silversea-branded napkins and menus and the opportunity to commune with fellow passengers. "They love that they're all Silversea guests, because they can all chat and talk about the trip, especially on the return," he said. Silversea president Bert Hernandez said the company is focused on evolving. "This enhanced guest journey to the Galapagos reflects this dedication -- streamlining every touchpoint to make visiting this bucket list destination more accessible and seamless than ever," he said. "We always put the guest at the center of everything we do, creating opportunities for deeper connections to the destination, and this is one more way we're leveraging our deep expedition and destination expertise to further elevate the Silversea experience." Lauwers said he expects other cruise lines to take a wait-and-see approach in deciding whether to operate their own Galapagos charter flights, but those that might consider it would also be in the luxury space. "I think they've got quite a niche in the Galapagos," Lauwers said of Silversea. "I think that'll be a big differentiator for them."
Travel Weekly
an hour ago
- Travel Weekly
American Express is opening a Centurion Lounge at Tokyo Haneda
American Express will open a Centurion Lounge at Tokyo's Haneda Airport on Wednesday. Located in Terminal 3 near Gate 114, the lounge is nearly 7,500 square feet and features "sweeping views of the airfield," American Express said in a release. In addition to a wide range of seating choices, lounge guests will have access to private phone booths that can also be used for meditation. Lined with fabric panels and featuring traditional Japanese artwork, the booths will have an audio program with calming sounds. A VIP area for Centurion members will feature elevated furnishings and finishes, with kumiko-style woodwork, Japanese art and photography and a private beverage station. The lounge's menu was created by chef Satoshi Ogino. It will have some traditional Japanese offerings like sushi and ramen as well as a buffet serving local and global cuisine. A sweets bar will feature tea and Japanese wagashi sweets. The lounge will also feature an open kitchen where guests can watch chefs at work. Its full bar will feature wine, cocktails, Japanese beers, sake and shochu. The Haneda lounge is the 30th Centurion Lounge to open and the fourth in Asia. "We've seen incredible demand for travel to Japan. It is one of the destinations where we've seen the highest growth recently," said American Express Travel president Audrey Hendley. "We look forward to showcasing the impeccable service Centurion Lounges are known for in a destination we know is so important to our card members."
